Frequency and number of neuroendocrine tumor cells in prostate cancer: No difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy

Prostate

Volumn 67, Issue 6, 2007, Pages 645-652

  Shimizu, Shinichiro ^a,b   Kumagai, Jiro ^a   Eishi, Yoshinobu ^a   Uehara, Toshitaka ^b   Kawakami, Satoru ^a   Takizawa, Touichiro ^a   Koike, Morio ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Funabashi Municipal Medical Center   (Japan)

Author keywords

Androgen deprivation; Chromogranin A; Neuroendocrine differentiation

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; TISSUE SECTION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CELL COUNT; CHROMOGRANIN A; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEUROENDOCRINE TUMORS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247607607     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20493     Document Type: Article

References (18)

1. Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med 1984;311:1281-1286.
2. Smith DC, Dawson NA, Trump DL. Secondary hormonal manipulation. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, editors. Genitourinary oncology. 2nd edition. Philadelphia: Lippincott Williams & Wilkins; 2000. pp 855-876.
3. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70(Suppl 1):254-268.
4. Sauer CG, Roemer A, Grobholz R. Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma. Prostate 2006;66:227-234.
5. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994;91:5330-5334.
6. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res 1999;59:3821-3830.
7. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45:586-592.
8. Tokunaga M, Yasuda M, Osamura RY, Itoh J, Mukai M, Shima M, Usui Y, Masuda A, Miyakita H, Terachi T. Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer. Oncol Rep 2005;13:1081-1087.
9. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998;51:585-589.
10. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer Suppl 1995;75:1850-1859.
11. di Sant'Agnese PA, Cockett ATK. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357-361.
12. di Sant'Agnese PA. Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: A review of morphologic aspects. Urology 1998;51(Suppl 5A): 121-124.
13. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. 6th edition. New York: Wiley-Liss Inc; 2002.
14. Gleason DF. Histological grading and clinical staging of prostatic carcinoma. Philadelphia: Lea & Febiger; 1977. pp 171-197.
15. Pinault S, Têtu B, Gagnon J, Monfette G, Dupont A, Labrie F. Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide. Urology 1992;39:254-261.
16. Berruti A, Dogliotti L, Mosca A, Tarabuzzi R, Torta M, Mari M, Gorzegno G, Fontana D, Angeli A. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients. Prostate 2001;47:205-211.
17. Grobholz R, Griebe M, Sauer CG, Michel MS, Trojan L, Bleyl U. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol 2005;36:562-570.
18. Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K, Ichikawa T. Changes in chromogranin A serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol 2005;48:224-229.